Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFNγ/IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis by unknown
PERSPECTIVE
Reciprocal Regulation of Substance P and IL-12/IL-23
and the Associated Cytokines, IFNγ/IL-17: A Perspective
on the Relevance of This Interaction to Multiple Sclerosis
Janek Vilisaar & Kiyokazu Kawabe & Manjit Braitch & Jehan Aram &
Yasemin Furtun & Angela J. Fahey & Mark Chopra & Radu Tanasescu &
Patrick J. Tighe & Bruno Gran & Charalabos Pothoulakis &
Cris S. Constantinescu
Received: 27 January 2014 /Accepted: 19 January 2015 /Published online: 18 February 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The neuropeptide substance P (SP) exhibits
cytokine-like properties and exerts different effects in au-
toimmune inflammation. Various immune cells express SP
and its neurokinin-1 receptor (NK1R) isoforms. A role for
SP has been demonstrated in a number of autoimmune
conditions, including multiple sclerosis (MS). In this
work, we studied the role of SP and NK1R in human
immune cells with a focus on their relationship with IL-
12/IL-23 family cytokines and the associated IFN-γ/IL-
17. AIMS: (1) To determine the role of SP mediated ef-
fects on induction of various inflammatory cytokines in
peripheral blood mononuclear cells (PBMC); (2) to inves-
tigate the expression of SP and its receptor in T cells and
the effects of stimulation with IL-12 and IL-23. Quantita-
tive real-time PCR, flow cytometry, ELISA, promoter
studies on PBMC and primary T cells from healthy vol-
unteers, and Jurkat cell line. Treatment with SP signifi-
cantly increased the expression of IL-12/IL-23 subunit
p40, IL-23 p19 and IL-12 p35 mRNA in human PBMC.
Expression of NK1R and SP in T cells was upregulated by
IL-23 but a trend was observed with IL-12. The IL-23
effect likely involves IL-17 production that additionally
mediates IL-23 effects. Mutual interactions exist with SP
enhancing the cytokines IL-23 and IL-12, and SP and
NK1R expression being differentially but potentially syn-
ergistically regulated by these cytokines. These findings
suggest a proinflammatory role for SP in autoimmune
inflammation. We propose a model whereby immunocyte
derived SP stimulates Th1 and Th17 autoreactive cells
migrating to the central nervous system (CNS), enhances
their crossing the blood brain barrier and perpetuates in-
flammation in the CNS by being released from damaged
nerves and activating both resident glia and infiltrating
immune cells. SP may be a therapeutic target in MS.
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Introduction
Substance P (SP) is an ubiquitously found 11-amino acid pep-
tide with a number of biological functions. It belongs to the
family of tachykinins, which also includes neurokinin A,
neurokinin B, neuropeptide K, neuropeptide Y, and
hemokinin-1. SP is generated through the enzymatic cleavage
of pre-pro-tachykinin A, which is encoded by the TAC1 gene.
Splice variants of TAC1 also generate neurokinin A and neu-
ropeptide K. The role of SP in pain pathways and neurogenic
inflammation has been well established, including effects of
vasodilatation and plasma extravasation. With its effects on
smooth muscle, SP is known to be involved in motility of
different organ tracts as well as stimulation of glandular secre-
tion and modulating autonomic reflexes.
SP originates from several cellular sources. It is released by
peripheral nerve endings and central terminals of sensory neu-
rons in the central nervous system (CNS). In addition, it is
produced by a variety of cells of the immune system. This,
and the presence of its receptor, the neurokinin-1 receptor
(NK1R) on cells of the immune system, suggest a role for
SP in immune responses. Immunomodulatory properties and
its role in autoimmune inflammation have only recently been
investigated in more detail. A role for SP has been demonstrat-
ed in neuroimmune and systemic autoimmune/inflammatory
conditions, including multiple sclerosis (MS), rheumatoid ar-
thritis and inflammatory bowel disease (Goode et al. 2000;
Kostyk et al. 1989; Lotz et al. 1987; O’Connor et al. 2004;
Weinstock 2014), as well as in infections and cancer.
NK1R is a widely expressed G-protein coupled receptor,
which can be expressed as a full length receptor in neuronal
and non-neuronal cells, and a recently studied truncated iso-
form (NK1R-T), expressed in monocytes and other peripheral
cells (Douglas and Leeman 2011). There is evidence that the
proportion of the full length and truncated receptor varies by
cell type and in disease states, such as inflammation and can-
cer (Chernova et al. 2009; Douglas and Leeman 2011).
In this article we discuss the interactions of SP and NK1R
with the IL-12/IL-23 family of inflammatory cytokines with
emphasis on the role of these molecules in neuroinflammatory
conditions, including MS and its animal model, experimental
autoimmune encephalomyelitis (EAE).
SP and NK1R are involved in neuroimmune communica-
tion, being abundantly expressed in the nervous system and its
sensory nerve projections into peripheral immune organs, and
immune cells themselves (lymphocytes, cells of monocyte
lineage, dendritic cells, eosinophils, mast cells etc.). SP is
involved in both innate and adaptive immune responses. The
functions of SP involve induction of cytokines (see below),
activation of immune cells (Nio et al. 1993; Scicchitano et al.
1988), modulation of T helper phenotype commitment
(Brogden et al. 2005; Cunin et al. 2011; Levite 1998), chemo-
taxis (Ahluwalia et al. 1998; Ruff et al. 1985; Schratzberger
et al. 1997), expression of adhesion molecules and effects on
the blood–brain barrier (Matis et al. 1990; Vishwanath and
Mukherjee 1996). A number of these effects have been linked
to NK1R dependent activation of NFκB.
The effects include stimulation of the production of IL-1,
IL-6, IL-8, IL-10, TNF-α from monocytes and macrophages
(Ho et al. 1996; Kincy-Cain and Bost 1997; Laurenzi et al.
1990; Lotz et al. 1988), and IL-1, IL-2, IFN-γ, IL-4, IL-6,
TNF-α and IL-10 from T cells (Blum et al. 1993; Calvo
et al. 1992; Delgado et al. 2003).
Induction of IL-12 by SP has been demonstrated in the
murine immune system (Kincy-Cain and Bost 1997) but until
now not in the human immune system. IL-23 induction by SP
has been reported in human monocytes (Cunin et al. 2011). In
murine models, IL-12 has been shown to induce SP precursor
mRNA in macrophages via STAT4 pathway (Arsenescu et al.
2005) and NK1R expression by both IL-12 and IL-18 stimu-
lation via NFκB in T cells (Weinstock et al. 2003). Recently,
IL-12 and IL-23 have been found to induce SP synthesis in
murine T cells and macrophages, which can be regulated by
IL-10 and TGF-β respectively (Blum et al. 2008).
EAE is a widely used model of MS with which it shares
pathological, immunological, neurobiological, and clinical
similarities (‘tHart et al. 2011; Constantinescu et al. 2011).
IL-12-induced IFN-γ production is the hallmark of the Th1
immune responses, whereas IL-17 is the signature cytokine of
the Th17 proinflammatory pathway. Of note, studies showing
SP induction of IFN-γ suggest that direct stimulation of
NK1R is sufficent and the process does not require IL-12
(Blum et al. 2003). Moreover, although IL-23 is still thought
to be an important cytokine for the stimulation and mainte-
nance of the Th17 pathway, in particular in the human im-
mune system, studies have shown that TGF-β in a proinflam-
matory environment that includes IL-6 and possibly IL-1, is
responsible for Th17 differentiation (Bettelli et al. 2006). Al-
though some discrepancies are still unresolved (Jagessar et al.
2012; Sanvito et al. 2010), a great number of studies are con-
gruent in indicating a role for both Th1 and Th17 cells in MS
and EAE (Edwards et al. 2010).
Studies in EAE have shown suppression of the disease in
NK1R knockout mice and amelioration of T cell transfer EAE
by NK1R antagonist CP-96345 (Nessler et al. 2006; Reinke
et al. 2006). Additionally, the role for SP in the pathogenesis
of MS has been suggested by genome-wide linkage studies
highlighting SP precursor protein encoding TAC1 gene as a
possible susceptibility gene for MS (Cunningham et al. 2005;
Vandenbroeck et al. 2002).
In this work, we investigate the reciprocal regulation of
substance P and NK1R and the IL-12/23 family with their
associated inflammatory cytokines in the human immune sys-
tem. Our findings show many similarities with those seen in a
murine immune system, with relvance to many inflammatory
diseases. We offer a perspective of how these interactions
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place SP as an important mediator of neuroinflammatory
disease.
Methods
Cell Preparations and Cultures
PBMC were isolated from whole blood by standard density
gradient centrifugation. For T cell activation, PBMC were
cultured for 72 h with 10 μg/ml phytohemagglutinin (PHA-
P, Sigma-Aldrich) in 10 % FCS/RPMI media. After media
change, cells were stimulated with 1000 U/ml IL-2
(PeproTech) at 37 °C for 24 h. The resulting cells Bblasts^
are typically >95 % CD3+.
CD4+ cells were magnetically isolated using the human
CD4+ T cell Isolation Kit (Miltenyi Biotec, USA), following
the manufacturer’s protocol. These cells were then transferred
into a 24-well plate pre-coated overnight with 0.5 ml/well of a
mixture of anti-CD3 (0.5 μg/ml) (BD Pharmingen) and anti-
CD28 (2.5μg/ml) (BD Pharmingen) in PBS. The coated wells
were washed with 1 ml RPMI medium prior to CD4+ cells
transfer (106 cells/well).
The Jurkat T cell line (kindly donated by Professor David
Heery, School of Pharmacy, University of Nottingham, UK)
was used for NK1R promoter-reporter assay.
Stimulation of Cell Cultures
PBMC 106/ml were stimulated for 24 and 48 h with 10−6–
10−12 M SP (Sigma-Aldrich) with and without the presence
of NK1R antagonist CP-96345 (Pfizer) 10−5–10−6 M, its inac-
tive enantiomer CP-96344 (Pfizer) 10−5–10−6 M, anti-NK1R
antibody (Chemicon International Inc) 1:500 or 1:1000, lipo-
polysaccharide (LPS, E. coli serotype 0111:B4, Sigma-Al-
drich) 1 μg/ml. After stimulation, the supernatants were re-
moved and stored at -80 °C for ELISA. Stimulations with cy-
tokines were carried out at the following final concentrations:
10 ng/ml IL-12 (R&D Systems) with and without 2.5 μg/ml
anti-IFN-γ antibody (PeproTech EC), 10 ng/ml IL-23 (R&D
Systems) with and without 2.5 μg/ml anti-IL-17 antibody
(PeproTech), 10 ng/ml IL-17 (PeproTech), 10 ng/ml IFN-γ
(PeproTech) for 8 and 24 h for mRNA-level, and 24 and 48 h
for protein-level expression.
Flow Cytometry
Flow cytometry was performed for protein level expression of
NK1R in PHA-stimulated PBMC (T cell blasts). After over-
night incubation, stimulated T cell blasts were transferred into
FACS tubes and 20 μl EDTA 100 mM (Sigma-Aldrich) were
added to each tube and incubated for 5 min at room tempera-
ture, the cells were then fixed using formaldehyde 4 % (1 ml/
tube) and left for 5–10 min at room temperature prior to wash-
ing three times, each with 1 ml PBA (Phosphate Buffered
Albumin, containing 0.5 % bovine serum albumin in phos-
phate buffered saline), stained with 2.5 μl of monoclonal sur-
face antibodies (anti-CD3-ECD, clone UCHT1, Beckman
Coulter; anti-CD8-PeCy7, clone SFCI21Thy2D3, Beckman
Coulter; and anti-CD56-PE, clone HCD56, Biolegend, and
isotype control-PE, clone P3.6.2.8.1, eBioscience) and incu-
bated for 40 min in the dark at 4 °C. The cells were then
washed once with PBA and twice, each with 1 ml perm/wash
buffer (BD Biosciences), stained with 10 μl anti-NK1R-APC
antibody (R&D Systems, Clone 694501) and its isotype con-
trol (mouse IgG3-APC, clone 133316, R&D Systems) and
incubated in the dark at room temperature for 30 min. Cells
were washed once with perm/wash buffer, fixed with 0.4 ml
of 0.5 % formaldehyde and analysed.
Regarding CD4+ cells staining, 20 μl EDTA (100 mM)
and 1 ml formaldehyde 4 % were added as above. The cells
were washed three times with 1 ml perm/wash buffer and
10 μl anti-NK1R-APC antibody were added. The cells were
incubated for 30 min in the dark at room temperature, washed
once with 1 ml perm/wash buffer, and fixed with 0.4 ml form-
aldehyde 0.5 %. For flow cytometry experiments, FC500
(Beckman Coulter) flow cytometer and Weasel 3.1 software
were used. For data presentation, GraphPad Prism 6.0 soft-
ware was used. The quadrants were set in flow cytometry plots
using single colour control tubes, fluorescence minus one
(FMO) tubes, and isotype control tubes.
ELISA
Commercial kits were used for measuring concentrations of
IL-1β (R&D Systems) and the different IL-12 and IL-23 sub-
units in stimulated PBMC culture supernatants, as well as SP
in T blast supernatants. IL-12p40 (Diaclone), IL-12p70
(eBioscience) and IL-23 p19/p40 (eBioscience) kits were used
following manufacturer’s instructions with assay sensitivities
specified as follows: below 2.58 pg/ml for IL-1β, below
20 pg/ml for IL-12p40, below 15 pg/ml for IL-23 p19/p40
and 4 pg/ml for IL-12p70. For measuring SP in T blast super-
natants, Parameter™ SP ELISA kit (R&D Systems) was used
according to the instructions with 31.5 pg/ml as the mean
minimum detectable concentration of SP.
Quantitative Real-Time Polymerase Chain Reaction (PCR)
Quantitative real-time reverse transcriptase PCR was used to
assess mRNA abundance of IL-12, IL-23 subunits in PBMC
on stimulation with SP, and mRNA abundance of SP precur-
sor and NK1R isoforms in PHA/IL-2 T blasts that had been
stimulated with IL-12, IL-23, IL-17, IFN-γ. Total-RNA was
extracted by column extraction using RNeasy Miniprep Kit®
(Qiagen) following the manufacturer’s instructions: the
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homogenization step was performed by needle homogeniza-
tion. First strand cDNA synthesis was initiated from 0.5 μg
total RNA using random primers (Promega, USA) and
MMLV reverse transcriptase (Promega) using conditions
specified by the manufacturer in a final volume of 25 μl.
The following specific primer sequences were used for IL-
23p19 sense: 5 ′ctccctgatagccctgtg3 ′ , antisense: 5 ′
ga c t g agg c t t g g a a t c t 3 ′ ; f o r IL - 12p40 s en s e : 5 ′
ggagtaccctgacacctg3′, antisense: 5′agatgaccgtggctgagg3′; for
IL-12p35 sense: 5′ccactccagacccaggaatg3′, antisense: 5′
gacggccctcagcaggt3′; for NK1R-F (full length): sense 5′
gaatgaggacagtgacgaac3′, antisense 5′ttgtggaacttgcagtagaac3′;
for NK1R-T (truncated): sense 5′tcttcttcctcctgccctacatc3′; an-
tisense 5′tggagagctcatggggttggatcct3′; for TAC1: sense 5′
tcaatgggcaatgacaggta3′, antisense 5′tccgcagtagctgacacaac3′.
As an internal standard, β2-microglobulin (β2MG) with the
following primers was used: sense 5′ctccgtggccttagctgtg3′,
antisense 5′tttggagtacgctggatagcct3′ (primers from MWG
Biotech, Germany). For primer design Primer 3 software
was employed. Real-time PCR reactions were carried out
using the SYBR Green fluorescence method with SYBR
GreenMastermix (Stratagene) as specified by the manufactur-
er. All real-time PCR reactions were carried out in triplicate on
multiplex qPCR system Mx4000® (Stratagene) using default
thermal cycling conditions. Dissociation curves were included
routinely for each reaction for assessing product homogeneity.
For quantitation of transcripts, the relative standard curve
m e t h o d , d e s c r i b e d b y A p p l i e d B i o s y s t em s
(AppliedBiosystems 1997), was used. For the set of standards,
equal aliquots of undiluted cDNA from each sample were
pooled together and serially diluted (neat, 1:2, 1:5, 1:10,
1:20). Using the standard curve, the comparative threshold
cycle value was converted to nanograms of total RNA equiv-
alent, used for first strand synthesis for both the target gene
transcript and the housekeeping gene, β2MG. Subsequently,
the values of individual sample mRNA abundance for the
target gene were normalized with the corresponding values
of β2MG. The reaction efficiency was optimal with template
in 1:5 dilution and primer concentrations 10 pmol/μl; for
TAC1 reaction the concentration of primers 2 pmol/μl and
1:5 template dilutions were used for optimal efficiency.
Transfection of Jurkat Cells With NK1R Promoter-Reporter
Construct and Luciferase Reporter Assay
The vector for the NK1R promoter activation assay was pre-
pared by transforming E coli DH5α –T1 competent cells
(Invitrogen) with human NK1R gene promoter 1,837-bp frag-
ment, cloned into luciferase expression vector pGL3-Basic
(Promega) . For incorporation of the vector into Jurkat cells,
2×107 cells/400 μl ice-cold PBS were transferred into each
electroporation cuvette (Invitrogen) and kept on ice for 10
mins. Subsequently, 3 μg prepared NK1R promoter-reporter
plasmid (containing Photinus pyralis luciferase) and 0.3 μg
Renilla reniformis luciferase reporter vector (Promega) as an
incorporation control were added per cuvette and pulsed on
Gene Pulser X cell™ (Biorad) with 250 V and 950 μF. After
electroporation, cells were kept in 10 % FCS/RPMI overnight
at 37 °C, 5 % CO2. Following stimulation of transfected cells
with cytokines as above for 24 h, cells were washed with PBS
and passively lysed according to the Dual-Luciferase Reporter
Assay protocol (Promega), whilst kept on a shaker for 15 min.
The lucifearase activities of each lysate were sequentially read
on TD-20/20 single-sample luminometer (Turner Designs) by
adding initiation/stop reagents (Promega) per protocol. Back-
ground luminescence of non-transfected control was
subtracted from individual sample values and ratios of
Photinus/Renilla luciferase signals were calculated.
Statistical Analysis
Data were analysed using nonparametric tests: Friedman test
for comparisons of means of ordinal data, orWilcoxon test for
continuous variables. SPSS 16.0 software was employed for
analysis. Differences were considered statistically significant
when p was ≤0.05.
Results
Protein-Level Expression of IL-1β and IL-12p40 in PBMC
Stimulated with SP
PBMC (106/ml) were stimulated with SP 10−6, 10−9 and
10−12 M, and IL-1β and IL-12p40 were measured by ELISA
after 36–48 h. SP alone was unable to induce detectable IL-1β,
unless co-stimulation with bacterial lipopolysaccharide (LPS)
was used (data not shown). SP 10−6 M enhanced IL-12p40
from 53 (±36) pg/ml to 135 (±2) pg/ml (p=0.02). Lower con-
centrations of SP failed to induce IL-12p40 in the absence of
co-stimulation with LPS (data not shown). Because the
amounts of IL-12p40 are likely to be too low to correspond
to detectable levels of IL-12p70 or IL-23 protein by ELISA, we
measured the mRNA expression of the IL-12 family cytokines.
mRNA-Level Expression of IL-12 and IL-23 Subunits
in PBMC on Stimulation with SP
To assess IL-12 and IL-23 induction by SP in PBMC, exper-
iments with a 24-h induction of the IL-12/23p40, IL-12p35
and IL-23p19 subunit mRNAwere done on 5 healthy volun-
teers. The expression of the three IL-12 and IL-23 subunits
showed a similar response to stimulation with SP and suppres-
sion by CP-96345 (specific NK1R antagonist), but not by CP-
96344 (control with no antagonist properties). SP strongly
upregulated the expression of the subunits to a degree similar
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to LPS (Fig. 1a). The induction of the p40 subunit by SP was
greatest with a 6.2-fold increase (p=0.043), followed by p19
and p35 induction with a 2.7-fold (p=0.068) and 2.3-fold (p=
0.043) increase in their expression respectively.
The product homogeneity and size for each of the condi-
tions was confirmed on agarose gel electrophoresis with a
product size of 131 bp for IL-12/23p40, 62 bp for IL-12p35,
109 bp for IL-23p19 and 148 bp for β2MG.
Expression of NK1R and SP in Lymphocyte Populations
and Effects of IL-12 and IL-23
The expression of the NK1R receptor on subgroups of human
immune cells is not well known. We determined this expres-
sion by flow cytometry using a directly conjugated antibody.
The percentages of NK1R+ cells in PHA-stimulated T cells
(Bblasts^), and subgroups of blasts based on expression of cell
surface markers CD3, CD8, and CD56, unstimulated or stim-
ulated with IL-12 or IL-23 for 24 h, and gated for CD3 (CD3-
PC7, NK1R-PE) can be found in supplemental Table 1 online.
In addition, the percentages of NK1R+ cells among the mag-
netically separated CD4+ T cells grown on anti-CD3/anti-
CD28-coated plates and stimulated as above are shown in
the table.
Both IL-12 and IL-23 appeared to modestly (not statistical-
ly significantly) increase NK1R in PHA-stimulated T cells
(Bblasts^), and subgroups expressing CD3, CD8, and CD56
(Table 1 and Supplemental Figure 1 Online). Similar slight but
not statistically significant trends towards increased NK1R
expression were observed with 24 and 48 h stimulation with
IL-12 plus IL-18, IL-18, IL-23, IL-17 and IFN-γ (not shown).
For SP peptide induction, two separate ELISAs were run
on supernatants of stimulated T cells from 5 control subjects
(Fig. 1b). Peptide level SP expression showed a great deal of
variability between subjects. None of the stimulation condi-
tions studied, i.e. IL-12, IL-12 plus anti-IFN-γ, IL-23, IL-23
plus anti-IL-17, IL-18, or IL-12 plus IL-18 showed effects that
were statistically significant at the protein level.
mRNA Level Induction of NK1R and SP in T Cells
The results shown so far, regarding NK1R, refer to the full-
length transcript. We have examined the NK1R isoform ex-
pression in T cell blasts with similar expression of the
Fig. 1 aQuantitative PCR results
showing IL-12p35, IL-12/23p40
and IL-23p19 mRNA abundance
in PBMCs in response to 24 h
incubation with different stimuli.
The values represent arbitrary
units after normalization with
corresponding values of β2MG
as an internal standard. Each bar
represents averages of 5 different
healthy donors, error bars indicate
SEM; b representative results
from one healthy donor showing
molar concentrations of SP (times
10−12 M) in cell culture
supernatants on ELISA, follow-
ing a 24 h stimulation of T
blasts with different stimuli. The
concentrations are converted from
mass concentrations (pg/ml)
given on ELISA
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truncated (NK1R-T) versus full-length NK1R (NK1R-F;
BNK1R^ in this article refers to NK1R-F) isoform in
unstimulated T cell blasts (ratio of 1.13; 53 % versus 47 %,
respectively, p=0.95).
The effects of different cytokine stimuli on SP precursor
and NK1R mRNA level expression were studied in PHA/IL-
2-stimulated T cell blasts from 10 healthy volunteers. IL-23
significantly upregulated both NK1R (p=0.041) and TAC1
transcripts (p=0.022) (Fig. 2a and b). There was a trend to
upregulation of TAC1 and NK1R by IL-12 (Fig. 2). There-
fore, we restricted the NK1R-T analysis to the IL-23 stimula-
tion. We observed a preferential induction of NK1R-T upon
stimulation with IL-23 compared to NK1R-F (ratio 4:1; p=
0.007).
NK1R (p=0.037) but not TAC1 (p=0.203) expression was
also significantly upregulated by IL-17A (here referred to as
IL-17). Anti-IL-17 abolished the effects of IL-23 in inducing
TAC1 (p=0.041), but not NK1R (p=0.262) (Fig. 2). On the
other hand, anti-IFN-γ did not block IL-12 effects in these
experiments.
The above effects were studied over different stimulation
periods as IL-12 and IL-23 responses may prevail at different
stages of inflammation (Thakker et al. 2007). Stimulation for
8 and 24 h was used, as possible induction of secondary cy-
tokines to IL-12 and IL-23 stimuli may take time to initiate,
however, no differences were found in T cell blasts between 8
and 24 h. The results from a 4 h-stimulation as used by
Weinstock et al. (Weinstock et al. 2003) and Arsenescu et al.
(Arsenescu et al. 2005) were also not significantly different
from the effects at 8 and 24 h.
However, in the experiments done on CD4+ cells, a slight-
ly greater tendency for NK1R induction by IL-12 was seen at
24 h as compared to 8 h, and in SP induction by IL-23 at 8 h as
opposed to 24 h (Fig. 3). With the 8 and 24 h sets combined,
NK1R induction by IL-23 in CD4+ cells was significant (p=
0.043), and induction by IL-12 showed only a trend (p=
0.063).
NK1R Promoter Construct Activation in Jurkat Cells
IL-23 appears to be a potent inducer of the NK1R promoter
region with an average 6-fold increase in the reporter signal
ratio compared to the unstimulated cells (Supplemental Figure 2
online). In both of these experiments, anti-IL-17 in IL-23 stim-
ulated samples showed strong reduction of NK1R expression,
compared to the IL-23 stimulus alone. IL-12 and IFN-γ
Fig. 2 a Quantitative PCR was
used to assess mRNA-level
expression of NK1R relative to
internal standard β2MG. Each
bar represents an average of 10
stimulation assays on T cell blasts
from 10 different healthy donors
+/- SEM. The results of individual
assays were expressed in arbitrary
units of mRNA abundance,
normalised with the
corresponding values of β2MG;
b mRNA-abundance of TAC1
relative to internal standard
β2MG: mean ratios of
stimulation assays on T blasts
from 10 different healthy donors
+/- SEM
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showed little activation in these assays. IL-17, IL-18 and the
combination of IL-12 and IL-18 showed moderate effects with
2.1, 2.3 and 2.8-fold average increase from the baseline
respectively.
Discussion
While evidence exists for a potential role of SP in experimen-
tal and human autoimmune neuroinflammatory disease, and
the role of the IL-12 family and related inflammatory cyto-
kines is convincing, little is known to date about the induction
of the IL-12 family cytokines by SP in human immune cells or
about the effects of proinflammatory cytokines on the expres-
sion of NK1R in human immune cells (Weinstock 2014). In
animal models, SP induced or stimulated Th1 type and Th17
immune responses (Beinborn et al. 2010), or inhibited anti-
inflammatory cytokines as recently shown in murine dendritic
cells (Janelsins et al. 2013).
In our study on human PBMC, a small degree of induction
of IL-12p40 by SP was observed at the protein level. The
small amounts of IL-12p40 suggested that sensitivity of the
ELISAwould be too low to detect the heterodimeric cytokines
IL-12p70 and IL-23. The sensitivity of the Cytometric Bead
Array (CBA), lower than the individual ELISA, had been also
tested before ELISA measurements and found insufficient to
detect the heterodimeric cytokines in our series (data not
shown). Small effects of SP on IL-12 secretion are consistent
with the published report (Janelsins et al. 2013).
When studying mRNA-level expression of the individual
subunits, induction of all subunits is detectable. The highest
values were seen with p40, consistent with the role of p40 as
part of both IL-12 and IL-23. The common p40 may also be
found in free monomer and in homodimers form in the mouse
immune system. The mRNA abundance of both IL-12p35 and
IL-23p19 was lower than that of p40, whereas the abundance
of p19 was slightly higher than that of p35. The results suggest
potentially distinct molecular mechanisms for IL-12 and IL-
Fig. 3 NK1R and TAC1 mRNA
abundance in CD4+ cells
following 8 and 24 h stimulation
(10 ng/ml IL-12 or 10 ng/ml IL-
23), normalized with β2MG as
internal standard. The values
represent mean ratios of 4 healthy
donors +/- SEM
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23 induction by SP, possibly involving distinct signalling
pathways and downstream regulatory factors (Goodridge
et al. 2003) at translational level or post-translational process-
ing level as known for p35 (Murphy et al. 2000).
IL-12 induction by SP has been previously shown at
mRNA level in murine macrophages (Kincy-Cain and Bost
1997). In that study, SP agonist concentrations as low as
10−9 M were bioactive, while 10−6 M had an effect in our
study. In the study by Kincy-Cain, both IL-12p40 and IL-
12p35 mRNA were potently induced; however, an increase
in IL-12p70 expression was not detected. At the protein level
at 24 h, IL-12p40 was induced, however, no detectable secre-
tion of p70 occurred (Kincy-Cain and Bost 1997). We have
not tested p70 in our study. Additive effects of SP on LPS in
IL-12 induction were observed as were also seen in our ex-
periments on PBMC.
IL-23 upregulates both NK1R and SP precursor mRNA
and appears to be a stronger stimulus than IL-12 in human T
cells. Whereas IL-12 can act on both naïve and activated cells,
mainly activated cells are considered responsive to IL-23
(Parham et al. 2002).
In protein-level experiments, SP did not show consistent
induction by the cytokines used. However, too much signifi-
cance cannot be put on detected SP concentrations in cell
culture supernatants as SP is quickly inactivated in aqueous
solutions near physiological pH. The discrepancies between
the protein and mRNA level induction will be discussed fur-
ther below.
There was more pronounced inter-individual variability in
TAC1 than in NK1R expression. This is expected as there are
more factors known in TAC1 transcriptional and post-
transcriptional regulation, providing a source for variation.
These factors include transcriptional silencers repressing
TAC1 transcription in non-neuronal cells (Greco et al.
2007). Within exon 1 in TAC1 promoter region, adjacent to
NFκB site, two RE-1 silencer of transcription (REST) binding
sites have been identified (Greco et al. 2007). Additionally,
RNA-binding proteins and microRNAs regulate SP synthesis
(Greco and Rameshwar 2007; Murthy et al. 2008). Although
TAC1 mRNA is found ubiquitously in human non-neuronal
tissues (Pinto et al. 2004), some studies suggest the impor-
tance of preconditioning non-neuronal cells with inflammato-
ry stimuli for TAC1 expression. For example, IL-1α has been
shown to induce TAC1 and particularly SP translation in non-
neuronal cells (Greco and Rameshwar 2007).
Interestingly, we show that IL-23 stimulation increases the
proportion of NK1R-T transcript in T cells. This truncated
receptor has been implicated in the mechanisms whereby
chronic inflammation transits to malignancy, a mechanism in
which the IL-23/IL-17 pathways seems to play a role
(Chernova et al. 2009).
Both NK1R and the TAC1 promoter regions have NFκB
binding sites (Simeonidis et al. 2003; Takahashi et al. 1992).
Here we have shown that NK1R promoter is activated by IL-
23 and, as suggested by anti-IL-17 blocking effects, also by
IL-17. Both IL-23 and IL-17 are known to signal via NFκB,
consistent with our findings. Additionally, IL-18 showed sim-
ilar moderate effects as IL-17 on the promoter level. In the
work by Weinstock and colleagues (Weinstock et al. 2003)
and Arsenescu and colleagues (Arsenescu et al. 2005),
NK1R expression was induced by IL-12 and IL-18 in murine
T cells via NFκB, whereas SP induction in murine macro-
phages was responsive only to IL-12 via STAT4. In our study,
the effects of IL-18 and co-stimulation of IL-12 and IL-18,
activating NK1R promoter, were less than the effects of IL-23.
IL-12 alone showed no activation of NFκB-containing NK1R
promoter, and it is known to act via STAT4. SP synthesis has
been previously shown to be STAT4 independent (Blum et al.
2008).
IL-12 has previously been shown to induce SP which can
mediate IFN-γ production, potentiating IL-12 effects in mu-
rine cells (Blum et al. 1993, 2001). Thus, SP has been so far
suggested to be part of the Th1 pathway. In a more recent
study, IL-12 was shown to induce SP inmurine Tcells, where-
as IL-23 induced SP inmacrophages (Blum et al. 2008). In our
study, we also show evidence for SP pro-inflammatory effects
on IL-23 and IL-17 pathways in humans, and a prominent
effect of IL-17A and IL-23 on NK1R. Although less promi-
nent, the effects of IL-12/IFN-γ and their interaction with SP
and NK1R seem to follow the same directions as those seen in
the murine immune system and to indicate a synergistic effect
to the IL-23/IL-17 cytokines. In the stimulation of NK1R for
induction of IFN-γ, IL-12 may be in part redundant, as it has
been shown that NK1R ligation by SP directly induces IFN-γ.
The role of SP can be best summarized as of a pleiotropic
immune regulator. SP signalling involves activation of NFκB,
which underlies the regulation of various inflammatory genes,
explaining SP effects on chemotaxis and other inflammatory
mechanisms. One of the important mechanisms is SP partici-
pation in regulating cytokine pathways.
There are important proinflammatory cytokines such as IL-
6 that may be even more important for the development of
Th17 responses than IL-23. It is known that SP induces IL-6
(Blum et al. 1993; Calvo et al. 1992; Delgado et al. 2003). Our
preliminary multiple cytokine assays performed by cytometric
bead arrays (not shown) showed little or no induction of IL-6
by SP in PHA-stimulated PBMC. This paper focused primar-
ily on the IL-12 family of heterodimeric cytokines, in partic-
ular since some of the IL-12-SP regulation reports preceded
the discovery of IL-23.
SP modulation of immune activities is characterized by
mutual regulation. As SP regulates a multitude of cytokines
and its pathway is also regulated by inflammatory activity, the
reciprocal interactions between SP and its receptor and the IL-
12/IL-23 cytokines are unlikely to be specific to this family of
cytokines but more likely to be part of a wider interactive
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network. Preconditioning of cells may be important for opti-
mal SP effects, and similarly, priming of cells with SP can
enhance cytokine effects. Protein-level effects largely depend
on these multiple stimulatory conditions which are likely to be
present and undergo dynamic changes in vivo. In particular in
the context of inflammation, multiple inflammatory signals
may synergise to produce a powerful inflammatory effect.
The positive feedback loop between SP and proinflammatory
cytokines may be essential for the augmentation of the inflam-
matory response and various sites. In addition, this interaction
may play a role not only in augmenting, but also in maintain-
ing inflammation, leading to a chronic inflammatory state,
where recent evidence suggest the truncated NK1R (NK1R-
T) may play a role.
Role of SP and its Interaction With IL-12/IL-23
and Related Cytokines in Autoimmune
Neuroinflammation
As pointed out in a recent review on SP (Weinstock 2014), the
immunoregulatory effects of SP are wide, and this can mean
different or even opposite effects in different infections or
inflammatory diseases: a protective role in some and a detri-
mental role in others. Even in conditions with similar etiolo-
gies, the regulation of and by SP and NK1R can be different.
In inflammatory bowel disease, for example, there is initial
strong activation of innate immune responses, and SP and
NK1R are involved in this process. Thus blocking them could
be of benefit.
MS is an autoimmune disease mediated predominantly by
T cells (of Th1, Th17, and GM-CSF producing variety)
(Constantinescu and Gran 2014). Both innate and adaptive
immune responses play an essential role in MS (Podda et al.
2013)..
Where can the interaction of SP and NK1R with inflam-
matory cytokines investigated here occur in the autoimmune
neuroinflammation of MS? In the prevailing model,
autoreactive Tcells become activated in the periphery through
a variety of stimuli. SP plays an important role at this level, by
enhancing proinflammatory cytokine production by these T
cells, which can themselves produce more SP, up-regulate
NK1R, and stimulate antigen presenting cells to produce fur-
ther T cell stimulatory cytokines. This leads to an up-
regulation of Th17 and Th1 responses, and enhanced penetra-
tion of the blood brain barrier (through up-regulation of
NK1R and adhesion molecules on endothelial cells, among
other mechanisms). In the CNS, SP stimulating cytokines,
produced by infiltrating T cells and monocytes, and SP itself
further stimulate both CNS-intrinsic cells with immune func-
tions such as microglia and astrocytes. Consistent with this,
SP-immunoreactive astrocytes are found in MS lesions
(Kostyk et al. 1989), and CNS astrocyes and microglia ex-
press both IL-12 and IL-23 (Constantinescu et al. 2005). The-
se processes facilitate perpetuation of inflammation, and a
chronically activated microglia, as shown in progressive
stages of MS (Lassmann et al. 2012) (Fig. 4).
A recently discovered mechanism may shed light on the
complex role of TGF-β, which, in an inflammatory environ-
ment, induces Th17 responses. TGF-β reduces the otherwise
rapid internalization of NK1R, not only increasing its
Fig. 4 Schematic diagram
illustrating substance P (SP) and
cytokine interactions in
autoimmune demyelinating
disease (e.g. MS). For clarity,
only the main effects on pro-
inflammatory Th17 and Th1
pathways have been depicted
with thicker arrows representing
stronger responses suggested by
our study. Blue lines indicate
NK1R. SP effects are shown in
red. CNS central nervous system;
BBB blood–brain barrier; DC
dendritic cell; PBMC peripheral
blood mononuclear cell; MHCII
major histocompatibility complex
II; TCR T cell receptor
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availability to SP generated in CNS inflammation, with sub-
sequent enhancement of IFN-γ and IL-17 production, but also
leading to further Th17 differentiation of naive Tcells (Bettelli
et al. 2006).
The above proposed model indicates that blocking SP and
its receptor can have a beneficial effect in autoimmune inflam-
mation of the CNS such as occurs in MS, and that the effect
may persist in the chronic stages of the condition. In the well-
established MS model, EAE, the genetic absence of NK1R or
its suppression using a synthetic antagonist was beneficial in
the chronic stages of the disease (Reinke et al. 2006). In an-
other study, a different antagonist also had therapeutic effects
(Nessler et al. 2006). Notably, suppression of IFN-γ and of
adhesion molecules were associated with the beneficial
effects.
Given the similarity of the results presented here with those
from the murine experiments, we conclude that SP, in part
through its interaction with proinflammatory cytokines of
the IL-12/IL-23, contributes to the development and perpetu-
ation of autoimmune inflammation in the CNS, and it is a
strong candidate as a therapeutic target in MS.
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